Fresenius Kabi, LLC — Federal Contractor Profile
FRESENIUS KABI, LLC: $415.1M in Federal Contracts with No Recent Wins
Contractor Overview
Total Contract Value: $415,147,861 ($415.1M)
Total Awards: 6
Company Profile
FRESENIUS KABI, LLC is a leading provider of pharmaceuticals, medical devices, and infusion therapy solutions for the healthcare industry. The company specializes in developing and manufacturing intravenous (IV) solutions, parenteral nutrition, and infusion pumps, among other medical products. Their core capabilities include advanced drug delivery systems, sterile compounding, and patient care solutions. FRESENIUS KABI, LLC has a significant presence in the federal government market, supplying critical medical products and services to various agencies. However, the company has not secured any new contracts in recent years, indicating a stable but potentially declining business strategy. The lack of competitive bidding and the absence of specific agency clients suggest a reliance on existing relationships and a limited focus on new opportunities. The company's track record includes notable projects such as the supply of IV solutions and infusion pumps, which have been crucial for maintaining patient care in federal healthcare facilities. Their contract patterns reveal a business strategy focused on maintaining existing relationships rather than pursuing new opportunities, which could be a risk in a rapidly evolving healthcare market. Compared to industry peers, FRESENIUS KABI, LLC holds a dominant position in the medical products sector, but faces competition from other large pharmaceutical and medical device manufacturers. The company's outlook is stable, but it may need to adapt to changing market dynamics to maintain its market share.
Specializations
- Pharmaceuticals
- Medical Devices
- Infusion Therapy Solutions
- IV Solutions
- Parenteral Nutrition
- Infusion Pumps
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts were sole-source)
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 100%
Recompete Rate: 100% (all contracts are recompete/renewal)
Competitive Position
FRESENIUS KABI, LLC holds a dominant position in the medical products sector, particularly in the areas of pharmaceuticals and medical devices. The company's reliance on sole-source contracts and lack of competitive bidding suggest a strong market presence and established relationships with federal agencies. However, this also indicates a limited focus on new opportunities and potential risks if these relationships weaken or if new competitors emerge.
Value to Taxpayers
FRESENIUS KABI, LLC provides critical medical products and services to federal agencies, which are essential for maintaining patient care in healthcare facilities. The company's average contract size of $69.19 million suggests that the contracts are substantial, which could be a concern if the company is not competitive in securing these contracts. However, the company's track record of delivering essential medical products and services indicates that they provide good value for taxpayer money, especially given the importance of their products in healthcare settings.
Agency Relationships
FRESENIUS KABI, LLC has a moderate concentration of agency clients, but the lack of specific agency information makes it difficult to assess the depth of their relationships. The company's stable contract patterns suggest that they maintain strong relationships with federal agencies, but there is a risk of dependency on these existing contracts. The absence of new contracts in recent years could indicate a need to diversify their client base to mitigate this risk.
Red Flags
- 100% sole-source contracts: This indicates a lack of competitive bidding, which could lead to higher costs and reduced innovation.
- No recent contracts: The absence of new contracts in recent years suggests a stable but potentially declining business strategy.
- Moderate agency concentration: The company's reliance on a few key agencies could pose a risk if these relationships weaken or if new competitors emerge.
Green Flags
- Dominant market position: FRESENIUS KABI, LLC holds a strong position in the medical products sector, which provides a competitive advantage.
- Track record of delivering essential medical products: The company has a history of supplying critical medical solutions, which is essential for maintaining patient care.
- Stable contract patterns: The company's consistent recompete/renewal contracts suggest a stable business model.
Key Contracts
FRESENIUS KABI, LLC has secured several significant contracts with federal agencies, including the supply of IV solutions and infusion pumps. These contracts are crucial for maintaining patient care in healthcare facilities and are essential for the company's business. The company's track record of delivering these products and services indicates their reliability and expertise. However, the lack of new contracts in recent years suggests a need to diversify their client base and explore new opportunities. The company's focus on maintaining existing relationships rather than pursuing new opportunities could be a risk in a rapidly evolving healthcare market. The key contracts reveal that FRESENIUS KABI, LLC is well-positioned to continue providing critical medical products and services to federal agencies, but they may need to adapt to changing market dynamics to maintain their market share.
Frequently Asked Questions
What does FRESENIUS KABI, LLC do for the federal government?
FRESENIUS KABI, LLC provides pharmaceuticals, medical devices, and infusion therapy solutions to federal agencies. Their core capabilities include advanced drug delivery systems, sterile compounding, and patient care solutions. The company specializes in developing and manufacturing intravenous (IV) solutions, parenteral nutrition, and infusion pumps, among other medical products. Their products and services are essential for maintaining patient care in federal healthcare facilities.
How much taxpayer money does FRESENIUS KABI, LLC receive?
FRESENIUS KABI, LLC has secured $415.1 million in federal contracts, with an average contract size of $69.19 million. The company has not secured any new contracts in recent years, indicating a stable but potentially declining business strategy. The substantial contract sizes suggest that the company receives significant taxpayer money for their products and services.
Is FRESENIUS KABI, LLC good value for taxpayer money?
FRESENIUS KABI, LLC provides critical medical products and services to federal agencies, which are essential for maintaining patient care in healthcare facilities. The company's average contract size of $69.19 million suggests that the contracts are substantial, which could be a concern if the company is not competitive in securing these contracts. However, the company's track record of delivering essential medical products and services indicates that they provide good value for taxpayer money, especially given the importance of their products in healthcare settings.
How does FRESENIUS KABI, LLC win its contracts?
FRESENIUS KABI, LLC has won all of its federal contracts through sole-source procurement, indicating a lack of competitive bidding. The company's dominant market position and established relationships with federal agencies likely contribute to its ability to secure these contracts. However, this also suggests a limited focus on new opportunities and potential risks if these relationships weaken or if new competitors emerge.
What agencies use FRESENIUS KABI, LLC most?
FRESENIUS KABI, LLC has a moderate concentration of agency clients, but the lack of specific agency information makes it difficult to assess the depth of their relationships. The company's stable contract patterns suggest that they maintain strong relationships with federal agencies, but there is a risk of dependency on these existing contracts. The absence of new contracts in recent years could indicate a need to diversify their client base to mitigate this risk.
What are the risks of relying on FRESENIUS KABI, LLC?
The risks of relying on FRESENIUS KABI, LLC include the company's reliance on sole-source contracts, which could lead to higher costs and reduced innovation. The absence of new contracts in recent years suggests a stable but potentially declining business strategy. The company's moderate agency concentration could pose a risk if these relationships weaken or if new competitors emerge. However, the company's track record of delivering essential medical products and services indicates that they provide good value for taxpayer money, especially given the importance of their products in healthcare settings.
How does FRESENIUS KABI, LLC compare to similar contractors?
FRESENIUS KABI, LLC holds a dominant position in the medical products sector, particularly in the areas of pharmaceuticals and medical devices. The company's reliance on sole-source contracts and lack of competitive bidding suggest a strong market presence and established relationships with federal agencies. However, this also indicates a limited focus on new opportunities and potential risks if these relationships weaken or if new competitors emerge. Compared to industry peers, FRESENIUS KABI, LLC faces competition from other large pharmaceutical and medical device manufacturers, but it holds a strong market position in the medical products sector.
Recent Federal Contracts
Fresenius Kabi, LLC has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS Awards $86M for Bulk Pharma Group B, Including Acyclovir and Doxycycline,... | Department of Health and Human Services | $86.3M | N/A |
| HHS awards $35M to Fresenius Kabi for pharmaceutical preparations, impacting ... | Department of Health and Human Services | $35.1M | N/A |